14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CAPR vs CRMD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin).
Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. CAPR 28.0/100 SELL) and 1.20β · 107% Vol risk profile, whereas CAPR leads top-line expansion (-7.9% YoY revenue growth, 0.38x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
CRMD Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $384.7M market capitalization and 41.0% operating margin.
OpEx & R&D Reinvestment46.4% of Rev ($488M)
90D Engineering Disclosures0 Published
Investor FAQ CAPR vs CRMD Key Questions & Quantitative Answers
As of Nov 16, 2026, CorMedix Inc. (CRMD) is the stronger overall head-to-head candidate over Capricor Therapeutics Inc (CAPR) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas CRMD carries 53.2/100 (HOLD) at $4.92 (49.0x Forward P/E, 41.0% operating margin). Growth vs. Quality Trade-Off: CRMD earns the overall head-to-head edge with a stronger Unified Composite Score (53.2/100 HOLD vs. CAPR 28.0/100 SELL) and 1.20β · 107% Vol risk profile, whereas CAPR leads top-line expansion (-7.9% YoY revenue growth, 0.38x PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile CRMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAPR leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with CRMD at -47.7% YoY revenue growth and +6.7% YoY earnings growth on $1.05B TTM revenue (87.4% gross margin, 41.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CAPR cumulative revenue shifted -33.3% while CRMD shifted +675.0%. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus 46.4% of Rev ($488M) (0 disclosures) for CRMD.
CRMD screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas CRMD trades at 49.0x Forward P/E, 2.4x Trailing P/E, 3.79x PEG, and N/M EV/Revenue (74.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus CRMD (15.3% ROE) capital efficiency.
In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, CRMD carries 56.3% implied volatility (25th %ile, Compressed (<25th %ile)), a 0.69x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.20β · 107% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.